INSM Insmed Inc
Company Analysis
Latest News
🟢 Insmed is trading 11.34% up today after third-quarter revenue beat expectations
Insmed is trading 11.34% higher at $107.97 after third-quarter revenue of $524.4 million topped analyst expectations. - BRINSUPRI sales were $400.1 million;...
🟢 Insmed is trading 19.4% up in pre-market after Q3 revenue beat and higher full-year outlook
Insmed is trading up 19.41% at $115.80 in pre-market on October 29 after third-quarter revenue beat estimates and the company raised the lower end of its...
Insmed's third quarter revenue of $524M beat estimates driven by strong BRINSUPRI momentum
Insmed reported third quarter 2026 results featuring a revenue beat and upwardly revised guidance for its primary commercial assets. Total revenue of $524.4...
Insmed Inc Q3 2026 Earnings Preview: What Analysts Expect on October 29, 2026
For the third quarter of 2026, analysts expect Insmed to report consensus revenue of $499.06 million and an EPS of -$0.34, with the current stock price of...
🟢 Insmed is trading 29.8% up in after-hours trading with no confirmed catalyst identified
Insmed is trading at $124.94, up +29.78% after hours, with no confirmed company-specific announcement explaining the move. - Available reporting said no new...
🔴 Insmed is trading 4.45% down today as biotech sector falls
Insmed is trading at $97.22, down 4.45%, amid biotech weakness. - As of 10:23 a.m. EST on October 8, 2026, XBI was down 2.04% in the regular session. - There...
🔴 Insmed is trading 5% down today after CFO Sara Bonstein's October 30 departure
Insmed is now trading 5.07% lower at $105.49 as investors focus on CFO Sara Bonstein’s planned October 30 departure. - The company has begun searching for a...
Insmed Announces CFO Departure and Reaffirms Full-Year 2026 Financial Guidance
Insmed Incorporated announced that Chief Financial Officer (CFO) Sara Bonstein will be stepping down from her role. In the same announcement, the company...
🔴 Insmed is trading 4.6% down with no clear company-specific catalyst identified
Insmed is trading 4.6% down at $108.89, with no clear company-specific announcement explaining the October 1 decline. - The latest identified company-specific...
🔴 Insmed is trading 4.1% down today
Insmed is trading 4.11% lower at $116.56, with no definitive cause identified. - Shares are down despite broader U.S. indices moving modestly higher; the move...
Insmed Targets $188 as Goldman Sachs Sees Undervalued Biotech Pipeline
Goldman Sachs initiated coverage on Insmed Inc. with a Buy rating and a $188.00 price target. This valuation represents significant potential upside from the...
Insmed Secures FDA Priority Review for ARIKAYCE Expansion in Lung Disease
The U.S. Food and Drug Administration (FDA) accepted Insmed’s supplemental New Drug Application (sNDA) for ARIKAYCE. The agency granted Priority Review for the...
🟢 Insmed is trading 4.51% up in pre-market amid broad market gains
Insmed is trading at $125.41 in pre-market, up +4.51%, likely helped by a broad risk-on market lift. - No clear company-specific announcement was identified...
🔴 Insmed is trading 4.4% down today as biotech shares weaken broadly
Insmed is trading 4.4% down at $119.73 as biotechnology shares weaken broadly. - The XBI sector ETF is down 2.11% during the September 15, 2026 regular...
🟢 Insmed is trading 4.6% up today after Cantor Fitzgerald conference highlighted stronger commercial momentum
Insmed is trading $130.63 (+4.60%) after its September 9, 2026 Cantor Fitzgerald conference highlighted stronger commercial momentum. - Management raised its...
Insmed Unveils Phase 3 ARIKAYCE Data at ERS, Targeting Lung Infections
Insmed Incorporated presents five abstracts featuring new respiratory data at the European Respiratory Society (ERS) Congress today, September 5, 2026, in...
Insmed Clears the Last Major Regulatory Hurdle — But Can Brinsupri's Blockbuster Launch Justify a $27 Billion Valuation?
Shares surged 9.4% to $135.59 as Insmed locked in the final piece of its global regulatory trifecta. Japan's Ministry of Health, Labour and Welfare on August...
🟢 Insmed is trading 9.4% up in pre-market after Japan approved Brinsupri
Insmed is trading $135.59 (+9.44%) after Japan approved Brinsupri for non-cystic fibrosis bronchiectasis in adults and eligible children on August 24, 2026;...
Baker Bros. Advisors boosts stake in Insmed by 18.5%
Biotechnology-focused investment firm Baker Bros. Advisors increased its position in Insmed Incorporated. According to a quarterly filing with the SEC, the...
Insmed Wins Japan Approval for BRINSUPRI, First-Ever Bronchiectasis Treatment
Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Insmed’s BRINSUPRI (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis...